stockportfolio.pro
Stocks / SYRE vs TGTX
SYRE vs TGTX
Spyre Therapeutics, Inc. and TG Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Spyre Therapeutics, Inc. (SYRE) | TG Therapeutics, Inc. (TGTX) | |
|---|---|---|
| Market cap | $6.8B | $7.1B |
| Revenue (latest FY) | $0 | $616.29M |
| Net income (latest FY) | $-155.20M | $447.18M |
| Revenue growth (5y CAGR) | — | 426.7% |
| Net margin | — | 72.6% |
| Return on equity | -21.7% | 69.0% |
| P/E ratio | — | 16.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 3 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open SYRE — free Open TGTX — freeFrequently asked questions
Which is bigger, SYRE or TGTX?
TG Therapeutics, Inc. is larger by market capitalization — $7.1B versus $6.8B.
Which grows faster, SYRE or TGTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.